Other languages Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
2.43 ^USD	-0.82%		-3.95%	+37.29%

Apr. 09	Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	MT
Mar. 21	Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	Mar. 20
US Futures Flat in Wednesday's Premarket as Investors Await Fed's Interest Rate Decision	Mar. 20
Top Premarket Gainers	Mar. 20
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome	Jan. 10
Taysha Gene Therapies Gets Expanded Eligibility in Canada for Early Trial of Rett Syndrome Treatment	Nov. 29
Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients	Nov. 29
Taysha Gene Therapies Insider Bought Shares Worth $163,000, According to a Recent SEC Filing	Nov. 20
Taysha Gene Therapies Q3 Net Loss Widens Unexpectedly	Nov. 14
Taysha Gene Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees	Nov. 01
Sector Update: Health Care Stocks Mixed in Afternoon Trading	23-10-24
Taysha Gene Says New Preclinical Data Reinforce TSHA-102 Potential to Address Rett Syndrome Root Cause; Shares Rise	23-10-24
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy 30th Annual Congress	23-10-24
Pliant Therapeutics Appoints Chief Regulatory Officer	23-10-16
Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome	23-09-26
Taysha to End TSHA-120 Program in Giant Axonal Neuropathy; Shares Down After-Hours	23-09-19
Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy	23-09-19
Top Midday Gainers	23-08-29
Taysha Gene Therapies Shares Rise as Company Regains Compliance With Nasdaq Listing Rules	23-08-29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Other languages

Filters